COVID FEST!!

Quote






anonymous said:
In what works does a pharmaceutical company lower the bonus plan going into Q1.
Click to expand...

The bigger issue is that they think bonus plan is better. All the legacy shire folks in management want to talk about is how great it was selling Adderall XR and Vyvanse. Never hear any of them talk about how they also had Intuniv in the bag. One would think their Intuniv experience would be much more relevant to what we are currently trying to do. But what do I know? Apparently after 7 years, I’m still just a former b2b rep who doesn’t understand the industry.
 






anonymous said:
The bigger issue is that they think bonus plan is better. All the legacy shire folks in management want to talk about is how great it was selling Adderall XR and Vyvanse. Never hear any of them talk about how they also had Intuniv in the bag. One would think their Intuniv experience would be much more relevant to what we are currently trying to do. But what do I know? Apparently after 7 years, I’m still just a former b2b rep who doesn’t understand the industry.
Click to expand...

Intuniv struggled and they even had D2D interactions as it was initially launched with adjunct only. This in my opinion is the largest hurdle for us to overcome with our physicians. We can't tell them what to expect when prescribing Q with other products which is a HUGE deterrent for doctors to not write.

Also, serious question for GC: how is our bonus plan going to be structured in Q2 when patients start coming off Q for summer break?
 






anonymous said:
Intuniv struggled and they even had D2D interactions as it was initially launched with adjunct only. This in my opinion is the largest hurdle for us to overcome with our physicians. We can't tell them what to expect when prescribing Q with other products which is a HUGE deterrent for doctors to not write.

Also, serious question for GC: how is our bonus plan going to be structured in Q2 when patients start coming off Q for summer break?
Click to expand...

they aren’t gonna do anything. psychiatry sucks
 




























































anonymous said:
What do the nuts do at Supernus when the entire nation is tanking with Qelbree? They blame the reps. NUTS!!!!!!!!!
Click to expand...

it’s been said that Rockville is happy with the performance of Qelbree which I do find hard to believe. Esp since we reps are not doing cartwheels and most are making low bonuses. Wish they would be real with us.
 
























anonymous said:
Intuniv struggled and they even had D2D interactions as it was initially launched with adjunct only. This in my opinion is the largest hurdle for us to overcome with our physicians. We can't tell them what to expect when prescribing Q with other products which is a HUGE deterrent for doctors to not write.

Also, serious question for GC: how is our bonus plan going to be structured in Q2 when patients start coming off Q for summer break?
Click to expand...

im not happy with the company but I guess I’m confused as to why you can’t tell them what to expect with prescribing Q? I have faced zero huge deterrents with this drug.
 






anonymous said:
im not happy with the company but I guess I’m confused as to why you can’t tell them what to expect with prescribing Q? I have faced zero huge deterrents with this drug.
Click to expand...

If you are getting more than 60 scripts per week of Q then you are not facing deterrents from your doctors. You are likely having deterrents from your doctors but don't even realize it. Ever wonder why no prescriber is "adopting" this medication?
 












Top Bottom
Back
Quote